Pennsylvania-based SEED Therapeutics has leveraged the unmatched expertise of its founding team to develop a target-first molecular glue discovery ... for targeted protein degradation (TPD ...
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback